SAGE Therapeutics, Inc. (NASDAQ:SAGE) Q4 2023 Earnings Conference Call February 14, 2024 8:00 AM ET
Company Participants
Barry Greene - President, CEO & Director
Kimi Iguchi - CFO & Treasurer
Laura Gault - Chief Medical Officer
Chris Benecchi - Chief Business Officer
Ashley Kaplowitz - Director, IR
Conference Call Participants
Matt Leskowitz - Goldman Sachs
Anupam Rama - J.P. Morgan
Ritu Baral - TD Cowen
James Condulis - Stifel
Tazeen Ahmad - Bank of America
Brian Abraham - RBC Capital Markets
Poorna Kannan - Needham & Company
Laura Chico - Wedbush Securities
Neena Bitritto-Garg - Deutsche Bank
George Farmer - Scotiabank
Sumant Kulkarni - Canaccord Genuity
Phoebe Tan - Jefferies
Yatin Sunej - Guggenheim
Vikram Purohit - Morgan Stanley
Marc Goodman - Leerink Partners
Operator
Good morning. Welcome to SAGE Therapeutics' Fourth Quarter and Full Year 2023 Financial Results Conference Call. [Operator Instructions]. This call is being webcast live on the Investors and Media section of SAGE’s website at SAGErx.com. This call is the property of SAGE Therapeutics and recording, reproduction or transmission of this call without the express written consent of SAGE Therapeutics, is strictly prohibited. Please note that this call is being recorded.
I would now like to introduce Ashley Kaplowitz, Executive Director of Investor Relations and Capital Markets at SAGE.
Ashley Kaplowitz
Good morning, and thank you for joining SAGE Therapeutics' Fourth Quarter and Full-Year 2023 Financial Results Conference Call. Before we begin, I encourage everyone to go to the Investors and Media section of our website at SAGErx.com where you can find the press release and slides related to today’s call.
I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties and our actual results may differ materially. Please review the risk factors discussed in today's press release and in our SEC filings for additional details.
We will begin the call with prepared remarks by Barry Greene, our Chief Executive Officer, who will provide an overview of our progress during the fourth quarter and full year 2023. Our Chief Business Officer, Chris Benecchi, will provide an update on the ongoing commercialization of ZURZUVAE. We will also be joined by Laura Gault, our Chief Medical Officer, who will review recent progress and development activities across our programs. We will then be joined by Kimi Iguchi, our Chief Financial Officer, who will review the financial results from the fourth quarter and full year 2023. Mike Quirk, our Chief Scientific Officer, will be available for questions during the Q&A portion of the call.